Oct. 3 at 6:32 PM
$TSHA
The pullback appears to be profit-taking and macro-driven—not company-specific.
Todays momentum pullback is not from any negative company developments—just short-term volatility
What analyst are saying:
Robert W. Baird raised TSHA’s price target from
$7 to
$12, citing strong clinical data and regulatory clarity.
- Other firms followed suit:
- Needham:
$10 target, Buy rating
- Chardan Capital:
$10 target, Buy rating
- Wells Fargo:
$8 target, Overweight rating
- TSHA now has a consensus target of
$9 and Buy ratings from 9 analysts.
